As part of a preventive treatment plan for patients with cystic fibrosis (CF)…
Treat Cystic Fibrosis patients with Pulmozyme® along with other standard therapies to provide early benefit to their lungs.You must have Javascript enabled and Flash 8.0 or above to view Pulmozyme videos.
Please download Flash here
Indication
Daily administration of Pulmozyme Inhalation Solution in conjunction with standard therapies is indicated in the management of CF patients to improve pulmonary function. In patients with an FVC ≥40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics. Safety and efficacy of daily administration have not been demonstrated in patients for longer than 12 months.
Spotlight
Discover CF Living -
an email program designed to support you with tailored information to help you manage your journey with CF
Watch and listen to how Pulmozyme works.
Explore our videos that give real Pulmozyme patients an opportunity to share their story.
Contribute to the Cystic Fibrosis Community by sharing your experience of living with CF with other patients and caregivers.
Important Safety Information
Pulmozyme should be used in conjunction with standard therapies for CF. The most common adverse events reported include voice alteration, pharyngitis, laryngitis, rash, chest pain, and conjunctivitis. Pulmozyme is contraindicated in patients with known hypersensitivity to dornase alfa, Chinese hamster ovary cell products, or any component of the product.
Pediatric Use
Because of the limited experience with the administration of Pulmozyme to patients younger than 5 years, its use should be considered only for those patients in whom there is a potential for benefit in pulmonary function or in risk of respiratory tract infection.
